Kevin Kalinsky, MD, MS

Articles

SABCS 2021 Updates in CDK4/6 Inhibitors in Breast Cancer

February 7th 2022

Sara A. Hurvitz, MD; Aditya Bardia, MD, MPH; Patrick Neven, MD, PhD; and Kevin Kalinsky MD, MS, discuss SABCS 2021 updates on the use of CDK4/6 inhibitors in HR+/HER2 breast cancer.

Breast Cancer Treatment: Sequencing With Antibody-Drug Conjugates

February 3rd 2022

Clinical pearls regarding ways to integrate antibody-drug conjugates into treatment algorithms when managing patients with breast cancer.

ADC Therapies in Development in Breast Cancer

February 3rd 2022

An overview of novel antibody-drug conjugate therapies currently under investigation as presented at SABCS 2021.

SABCS 2021 Updates in ER+ Breast Cancer

January 31st 2022

Experts in the management of breast cancer review recent data on SERDs (selective estrogen receptor degraders) in ER+/HER2 advanced breast cancer presented at SABCS [San Antonio Breast Cancer Symposium] 2021.

Sacituzumab Govitecan Safety Profile in TNBC

January 28th 2022

Strategies that can be used to mitigate and manage adverse events associated with sacituzumab govitecan therapy for triple-negative breast cancer.

Sacituzumab Govitecan for TNBC

January 28th 2022

Komal Jhaveri, MD, FACP, provides rationale for treating a patient with triple-negative breast cancer with sacituzumab govitecan.

Managing Patients With MBC on T-DXd Therapy

January 21st 2022

Strategies used to help monitor and manage T-DXd treatment-related adverse events.

T-DXd for HER2+ Metastatic Breast Cancer

January 21st 2022

Recommendations for starting a patient with HER2+ metastatic breast cancer on T-DXd after prior T-DM1 therapy.

Dr. Kalinsky on Updated Results From the RxPONDER Trial in HR+/HER2- Breast Cancer

December 8th 2021

Kevin Kalinsky, MD, MS, discusses updated results from the phase 3 RxPONDER trial in patients with hormone receptor-positive, HER2-negative breast cancer.

Examining the Importance of the Institutional Perspectives in Cancer Webinars

April 2nd 2021

Jason Porter, MD, Subramanian Janakiraman, MD, Natalie S. Calendar, MD, Parameswaran Hari, MD, MRCP, and Kevin Kalinsky, MD, MS, discuss the importance of the Institutional Perspectives in Cancer webinars.

Dr. Kalinsky on the Potential Role of Ovarian Function Suppression in HR+/HER2- Breast Cancer

March 30th 2021

Kevin Kalinsky, MD, MS, discusses the potential role of ovarian function suppression in hormone receptor–positive, HER2-negative breast cancer.

Dr. Kalinsky on Initial Results of the RxPONDER Trial in HR+/HER2- Breast Cancer

December 9th 2020

Kevin Kalinsky, MD, MS, discusses the initial results of the phase 3 RxPONDER trial in patients with hormone receptor–positive, HER2-negative breast cancer.

Dr. Kalinksy on pCR as a Surrogate Marker for EFS in TNBC

April 3rd 2020

Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses the use of pathologic complete response (pCR) rate as a surrogate marker for event-free survival (EFS) in triple-negative breast cancer (TNBC).

Dr. Kalinsky on Clinical Impact of Atezolizumab Combo in TNBC

January 31st 2020

Kevin Kalinsky, MD, MS, discusses the clinical impact of the combination of atezolizumab and nab-paclitaxel in triple-negative breast cancer.

Dr. Kalinsky on CNS Involvement in HER2+ Breast Cancer

September 20th 2018

Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses central nervous system involvement in HER2-positive breast cancer.

Dr. Kalinsky Discusses the Evolution of HER2+ Breast Cancer

September 5th 2018

Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses the evolution of treatment for patients with HER2-positive metastatic breast cancer.

Dr. Kalinsky Discusses Biosimilars in Breast Cancer

August 10th 2018

Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical School, discusses the promise of biosimilars in breast cancer.

Dr. Kalinsky on Neratinib and Tucatinib in HER2+ Metastatic Breast Cancer

August 8th 2018

Novel Tomography System May Help Guide Therapy in Early Breast Cancer

January 8th 2014

Diffuse optical tomography (DOT) is a novel, fast, safe, and low-cost technique that uses near-infrared light to provide three-dimensional data on tissue vascularity without the use of radiation.